An observational study in Cochlear Hearing Loss, sponsored by Advanced Bionics AG. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Advanced Bionics AG (part of Sonova AG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Hearing Loss, Sensorineural by Sonova AG — 4 open to participants now, 4 under way, none of them phase 3. Hearing Loss, Sensorineural · Sonova AG.
Among the 28 studies in Hearing Loss, Sensorineural by Sonova AG, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 28th registered.
348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.
Browse Hearing Loss, Sensorineural studies →4 of the 28 studies in Hearing Loss, Sensorineural by Sonova AG are open now, in 8 countries. Recruiting first, the newest first:
Advanced Bionics AG · Sites in Belgium, France, Germany and 4 more countries
Ages 18+
Advanced Bionics AG · Sites in Germany
Sonova AG · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 1
First in 2015; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 51 is below the median of 70 across 86 observational studies indexed under Hearing Loss, Sensorineural.
Median enrollment 20 across the 21 interventional studies, 37 across the 7 observational. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Advanced Bionics AG, one of the names counted as Sonova AG. Under that name alone:
Advanced Bionics AG is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
2 of the studies in Hearing Loss, Sensorineural by Sonova AG that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894303Advanced Bionics AGEvaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up | 2026-12 |
| NCT06268340Advanced Bionics AGHearing and Structure Preservation Via ECochG | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Hearing Loss, Sensorineural by Sonova AG, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective and monocentric clinical investigation, non-interventional and non-randomized. The overall goal of this clinical study is to generate additional clinical data confirming the safety and efficacy of the remote programming functionality of Target CI version 1.5 and the AB Remote Support app. Hearing outcomes are expected to be similar whether a study subject's sound processor is programmed in the traditional method in the audiologist's office or whether programming is performed via remote fitting. Therefore, the study uses a non-inferiority design to determine whether sentence recognition in noise is no worse with remote fitting than in an in-office setting.
Advanced Bionics adults CI users
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Implanted with a HiResolution Bionic Ear System (HiRes 90K or HiRes 90K Advantage or HiRes Ultra or HiRes Ultra 3D) on at least one side
Exclusion Criteria:
Pregnancy and breast-feeding are not exclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Unilateral users
Device: Target CI v1.5 remote programming
Bilateral users
Device: Target CI v1.5 remote programming
Bimodal users
Device: Target CI v1.5 remote programming
Use of the remote programming function of Target CI v1.5 and the AB remote support application
50% SRT measured as signal to noise ratio in DB (French Matrix test in noise)
The primary efficacy objective is to demonstrate that speech recognition in noise after remote fitting is no worse than speech recognition in noise after in-office fitting.
Time frame: one-month chronic use of remotely fitted sound processor
Score in the Lafon phoneme test in quiet
The secondary efficacy objective is to demonstrate that speech recognition in quiet after remote fitting is no worse than speech recognition in quiet after in-office fitting.
Time frame: one-month chronic use of remotely fitted sound processor
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 42 observational studies under Hearing Loss, Sensorineural, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 13. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.